Cioteronel

Cioteronel
Clinical data
Other names	CPC-10997; Cyoctol; X-Andron
Routes of; administration	By mouth, topical
Drug class	Nonsteroidal antiandrogen
ATC code	None;
Identifiers
	IUPAC name 4-(5-methoxyheptyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one;
CAS Number	89672-11-7;
PubChem CID	55994;
ChemSpider	50555;
UNII	1RTH95874Z;
ChEMBL	ChEMBL2104105;
CompTox Dashboard (EPA)	DTXSID50869028 ;
Chemical and physical data
Formula	C16H28O2
Molar mass	252.398 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(CCCCC1CCC2C1CC(=O)C2)OC;
	InChI InChI=InChI=1S/C16H28O2/c1-3-15(18-2)7-5-4-6-12-8-9-13-10-14(17)11-16(12)13/h12-13,15-16H,3-11H2,1-2H3; Key:KDULJHFMZBRAHO-UHFFFAOYSA-N;

Cioteronel (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) (developmental code name CPC-10997; former tentative brand names Cyoctol, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed.^[1]^[2]^[3] It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness), and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.^[3]^[4]

References

^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 570. ISBN 978-0-412-46630-4.
^ Lednicer D (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
^ ^a ^b Tiwari A, Krishna NS, Nanda K, Chugh A (November 2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–72. doi:10.1517/13543784.14.11.1359. PMID 16255676. S2CID 25662071.
^ "Cioteronel". Adis Insight. Springer Nature Switzerland AG. Archived from the original on 2016-12-29. Retrieved 2016-11-25.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

[GanellinTriggle1996-1] Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 570. ISBN 978-0-412-46630-4.

[Lednicer1994-2] Lednicer D (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.

[TiwariKrishna2005-3] Tiwari A, Krishna NS, Nanda K, Chugh A (November 2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–72. doi:10.1517/13543784.14.11.1359. PMID 16255676. S2CID 25662071.

[AdisInsight-4] "Cioteronel". Adis Insight. Springer Nature Switzerland AG. Archived from the original on 2016-12-29. Retrieved 2016-11-25.

[1]

[2]

[3]

[4]

Clinical data

Other names	CPC-10997; Cyoctol; X-Andron
Routes of administration	By mouth, topical
Drug class	Nonsteroidal antiandrogen
ATC code	None
Identifiers
IUPAC name 4-(5-methoxyheptyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one
CAS Number	89672-11-7
PubChem CID	55994
ChemSpider	50555
UNII	1RTH95874Z
ChEMBL	ChEMBL2104105
CompTox Dashboard (EPA)	DTXSID50869028
Chemical and physical data
Formula	C₁₆H₂₈O₂
Molar mass	252.398 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCC(CCCCC1CCC2C1CC(=O)C2)OC
InChI InChI=InChI=1S/C16H28O2/c1-3-15(18-2)7-5-4-6-12-8-9-13-10-14(17)11-16(12)13/h12-13,15-16H,3-11H2,1-2H3 Key:KDULJHFMZBRAHO-UHFFFAOYSA-N

Cioteronel

See also

References